Exelixis beats Q3 estimates but stock edges lower on guidance
Exelixis (NASDAQ:EXEL) reported Q3 adjusted EPS of $0.94, beating estimates by $0.07, with revenues of $658.7M, up 10.2% YoY. FY2026 revenue guidance of $2.5B-$2.55B was maintained, slightly below analyst consensus. Shares fell 0.15% post-announcement. The company expects topline results from its phase 3 STELLAR-304 trial in Q1 2027 and updated its effective tax rate guidance to 16%-18%.
How this was made
The 30-second read
Why it matters
The article combines a Q3 beat with forward-looking items that affect valuation: FY 2026 revenue guidance midpoint slightly below consensus, explicit exclusion of zanzalintinib revenues from guidance, and a planned Phase 3 STELLAR-304 topline readout in 1Q 2027.
Market read
Traders should focus on whether the market is discounting the gap between current franchise cash flows and the later timing of zanzalintinib revenue visibility.
What to watch
Investors may be underweighting the updated effective tax rate guidance (16% to 18% vs prior 21% to 23%), which can partially offset operating cost pressure and improve net earnings trajectory.
Background
Exelixis is a biotech with a cabozantinib franchise and an additional asset, zanzalintinib, currently under FDA review for previously treated metastatic colorectal cancer.
Ticker impact
Exelixis reported Q3 adjusted EPS of $0.94 and revenue of $658.7M, but shares edged down after guidance and zanzalintinib-related outlook details.
Likely near-term pressure or choppy trading as the market weighs the slightly below-consensus FY revenue midpoint and waits for zanzalintinib revenue visibility.
The article provides both the upside (EPS and revenue beat) and the offset (FY 2026 midpoint below consensus, guidance excludes zanzalintinib, and Phase 3 topline timing is in 1Q 2027).
Market effects
Biotech investors may recalibrate expectations for cabozantinib franchise durability versus the contribution timing of next-gen assets under FDA review.
Limited, primarily affects US small/mid-cap biotech sentiment rather than broad regional risk.
Low, as the catalyst is company-specific clinical and guidance timing rather than a global macro shock.
Counterpoint
The guidance midpoint being slightly below consensus may be a conservative placeholder, while the Q3 cabozantinib franchise strength could still support upside if zanzalintinib de-risks faster than expected.
Key entities
- companyExelixis, Inc.
Reported Q3 results above consensus, maintained FY 2026 revenue guidance range, and provided timing for zanzalintinib Phase 3 topline.
- drug_candidatezanzalintinib
Under FDA review; Phase 3 STELLAR-304 topline results expected in 1Q 2027.
- product_franchisecabozantinib franchise
Primary revenue driver; US net product revenues rose year over year in the quarter.
